India ID Exchange · Board Seats
Audit Committee Chair Roles in Healthcare and Pharma Industry in Mumbai
Audit chair roles on Mumbai healthcare and pharma boards—joining inventory, R&D, quality, channel and regulatory evidence to the accounts.
Mumbai candidates are often evaluated across listed reporting, global regulator exposure and complex distribution. The differentiator is an ability to connect each financial judgement to its operational source.
- Seats on this page
- 0
- Open now
- 0
- Forecast to open
- 38
- Boards read daily
- 3,790
Company identity, per-firm fees, deadline and the full brief remain Foresight-only.
The seats
What is live now, what the filings suggest is approaching, and what changed on tracked boards.
Open audit committee chair seats—Mumbai healthcare and pharma
The page begins with the exact live cohort and never presents widened alternatives as exact matches. Fee bands stay public; per-company values do not.
No audit committee chair seat in Mumbai is open on the Exchange today.
Seats of this exact shape surface irregularly. The Exchange reads 3,790 boards every day and most appointments become visible weeks before they are advertised anywhere — Foresight members are matched to them as they form. The closely related seats below are open right now.
Get matched as these openSame seat, other cities (5)
audit committee chair seats in this sector outside Mumbai. Board seats rarely require relocation — most carry four to six meetings a year.
Healthcare Technology — Independent Director, Medication Safety and Clinical Pharmacy Systems
Urgent — Priority appointmentIndependent Director · Medication Safety, Clinical Pharmacy Systems & Health Informatics · Hyderabad · Initial term subject to applicable law, appointment process and shareholder approval where required
AuditRiskClinical TechnologyView seat & applyDirect Gladwin mandate · Approximately 24–30 days annually
Independent Director — Institutional Medicines Supply and Distribution | Finance Function, Inventory Integrity and Credit Governance
Medium Term — seat in ~3 monthsIndependent Director · Pharmaceutical Distribution & Institutional Medicine Supply · Kolkata · Initial term subject to applicable law, appointment process and shareholder approval where required
Audit (Chair)Finance & RiskView seat & applyDirect Gladwin mandate · 24–30 days annually, including warehouse and distribution reviews
Non-Executive Director — Biomedical Waste Treatment and Healthcare Environmental Services Company | Chain of Custody, Infection Risk and Environmental Compliance
Medium Term — seat in ~3 monthsNon-Executive Director · Biomedical-Waste Collection, Treatment & Healthcare Environmental Services · Kochi · Subject to the company's Articles, shareholder process, applicable permissions and Board approval
AuditRiskSafety, Environment & OperationsView seat & applyDirect Gladwin mandate · 22–28 days annually, including collection-route, treatment-facility and downstream-destination visits
Independent Director — IPO-Stage Companion Animal Care Network | Clinical Quality, Ethical Growth and Network Integration
Medium Term — seat in ~3 monthsIndependent Director · Companion-Animal Hospitals, Clinics & Care Services · Bengaluru · Initial term subject to applicable law, appointment process and shareholder approval where required
AuditClinical Quality & EthicsView seat & applyDirect Gladwin mandate · Approximately 28–34 days annually through IPO readiness and the first listed reporting cycle
Independent Director — PE-Backed Occupational Health and Workforce Medical Services | Clinical Independence, Employer Contracts and Integration
Medium Term — seat in ~3 monthsIndependent Director · Occupational Health, Workforce Medical Services & Employer Wellness · Hyderabad · Three years, subject to shareholder approval and annual independence review
AuditRiskClinical Quality & EthicsView seat & applyDirect Gladwin mandate · Approximately 24–30 days annually, including clinical and workplace-service visits
What is hidden on the 5 seats above
- · The company behind each mandate, where it has authorised disclosure
- · Sitting fees, committee fees and annual retainer — always members-only
- · The application deadline and the full mandate brief
- · Direct application, without waiting for a seat to open to free members
Audit Committee Chair Roles in Healthcare and Pharma Industry in Mumbai is a narrow, high-competition shape. Foresight members apply the day a seat is posted, up to ten a day; free members wait for the deadline window and a cap of one application a week. On a shortlist of five, that timing is the contest.
Unlock with ForesightSeats forecast to reach a term boundary
The latest filings record 284 sitting chairs in this cohort. The counts below are term-boundary signals, not announced vacancies; reappointments and early exits can move the date.
22
First term completing
Four to five years served; the board can renew or reopen the skills question.
12
Second term completing
Nine to ten years served; a further consecutive term is unavailable.
4
Past ten years
A succession signal that requires examination, not a claim about any named director.
Board movements in the latest filing period
Exchange filings for Jun 2026 recorded 62 appointments and 54 departures in this page’s measured market. These are filed movements, not inferred vacancies.
| Movement | Board | Director | Filed category |
|---|---|---|---|
| Appointed | Cipla Limited | Achin Gupta | Executive Director |
| Departed | Cipla Limited | Umang Vohra | Executive Director |
| Appointed | Sun Pharmaceutical Industries Limited | Satyavati Berera | Non-Executive - Independent Director |
| Appointed | Sun Pharmaceutical Industries Limited | Andreas Busch | Non-Executive - Independent Director |
| Appointed | Abbott India Limited | Neeraj Jain | Non-Executive - Independent Director |
| Appointed | Abbott India Limited | James Wenner | Non-Executive - Non Independent Director |
| Appointed | GlaxoSmithkline Pharmaceticuals Limited | Ronojit Biswas | Executive Director |
| Appointed | SANOFI INDIA LIMITED | Siraj Chaudhry | Non-Executive - Independent Director |
| Appointed | SANOFI INDIA LIMITED | Rajani Kesari | Non-Executive - Independent Director |
| Appointed | NEULAND LABORATORIES LIMITED | Mauricio Futran | Non-Executive - Non Independent Director |
The market
The incumbent pool, term pattern, concentration, committee resilience, representation and disclosed pay.
Who holds this seat today
Healthcare audit-chair data is queried independently from the financial-services reference. Sample size and period are shown wherever the data supports a block.
284
Sitting chairs
1
Median listed boards
21.4%
Holding 3+ boards
7.5 : 1
Incumbents / boundary
Tenure profile
25
Appointments in 12 months
Filed arrivals only; cessation data is not populated well enough to publish reasons for departure.
8.8%
Observed arrival rate
This is not converted into an implied tenure; that inference conflicts with the measured histogram.
55.6%
Newcomers on one board
Capacity, not an already-large portfolio, is visible in the newly appointed cohort.
Where the incumbent seats sit by company size
The governance dataset carries one flat sector label, so this block uses disclosed market-cap bands. It does not invent bank, software or pharma sub-sectors that the filings do not contain.
Committee floor and representation
39.3%
At the three-member floor
2
Below three members in the filing
23.9%
Women among recorded chairs, versus 29.3% of members
What the seat pays
Public bands answer the market question without exposing the company-specific figure. The rows below are computed from 234 annual-report records; each denominator is shown.
| Benchmark | P25 | Median | P75 | P90 |
|---|---|---|---|---|
| Board meeting n=50 | ₹25,000 | ₹50,000 | ₹1 lakh | ₹1 lakh |
| Committee meeting n=43 | ₹25,000 | ₹50,000 | ₹1 lakh | ₹1 lakh |
| Annual per ID n=58 | ₹1.5 lakh | ₹4 lakh | ₹12.8 lakh | ₹30 lakh |
| Highest-paid ID n=58 | ₹2 lakh | ₹5.2 lakh | ₹18 lakh | ₹30 lakh |
Ranges across companies, not offers. Per-company fees remain gated on each seat’s own detail page.
Open the ID salary benchmarkThe seat itself
The work behind the title, the sector-specific judgement it requires, and the evidence a nomination committee will test.
What the role actually owns
Reporting
Financial reporting judgement
Challenge estimates, materiality, impairment and disclosure choices before the accounts reach the board.
Controls
Controls and assurance
Connect the internal-control map to internal audit, statutory audit and management remediation without letting gaps fall between owners.
Assurance
Auditor independence
Approve the audit relationship, scrutinise non-audit services and create space for the auditor to speak without management.
Conduct
Whistleblowing and investigation
Protect escalation channels, commission proportionate investigations and keep remediation separate from reputation management.
Why healthcare assurance extends beyond the ledger
Inventory shelf life, channel returns, price controls, research spend, acquisitions and regulatory observations can all change financial reporting. The audit chair must join financial evidence to quality, clinical and distribution systems.
Inventory
Inventory carries expiry and quality risk
Valuation depends on shelf life, batch status, demand, returns and whether stock can legally remain in the channel.
Pipeline
Research creates judgement
Development spend, milestone income, licences and impairment require evidence about technical and commercial probability.
Exposure
Compliance can become a provision
Inspection observations, recalls, price-control disputes and litigation require disciplined probability and disclosure judgements.
Do you qualify for this seat?
A credible chair can trace a financial conclusion back to batch, trial, channel and regulatory evidence while keeping the auditor independent.
01 · Reporting
Inventory and revenue depth
Challenge expiry, returns, rebates, channel loading and cut-off with operational evidence.
02 · Pipeline
R&D accounting judgement
Understand capitalisation, collaboration income, milestones, intangibles and impairment.
03 · Quality
Quality-system literacy
Connect deviations, CAPA, data integrity and recalls to provisions, controls and disclosure.
04 · Compliance
Regulatory-exposure judgement
Separate observation, remediation, probability and material disclosure without minimising uncertainty.
05 · Conduct
Investigation governance
Protect whistleblowing and evidence in sales practice, trial, quality and procurement matters.
06 · Coverage
Assurance integration
Align statutory audit, internal audit and quality assurance without blurring their accountabilities.
Doing the job
The dated obligations, the first hundred days, and a practical checklist for the work behind the appointment.
The regulatory year
The healthcare audit calendar replaces the RBI row with CDSCO, quality, clinical and price-control evidence that can affect estimates and disclosure.
First board meeting of the year
Companies Act s.149(7)
Record each independent director's declaration and test conflicts against the current group structure, not last year's chart.
At least once each financial year
Applicable LODR committee regulation
Meet the statutory minimum, but schedule decisions when the evidence is available; an annual formality is not active oversight.
Annual independent-director meeting
LODR Reg. 25(3)
Use the session without management to surface information gaps and agree what must return to the full board.
Before the annual evaluation
LODR Schedule II
Set evaluation criteria before scoring begins and preserve the evidence behind difficult conclusions.
By 30 September
MCA DIR-3 KYC
Confirm every DIN remains active. Administrative lapse can disable a director at the point a committee most needs continuity.
Before quarterly and annual results
LODR Reg. 18/33 and applicable Ind AS
Test inventory, returns, research arrangements, intangibles, provisions and material regulatory matters before recommending results.
After material quality or regulatory events
Drugs and Cosmetics / CDSCO / NDCTR framework
Connect root-cause evidence, recall or remediation scope and regulator correspondence to control, provision and disclosure decisions.
Provision summaries are orientation, not legal advice. Verify the current Act, Listing Regulations and sector direction before relying on an item.
Your first hundred days
The first hundred days should connect audit evidence to the product and patient systems that create the numbers.
Days 1–15
Meet finance and quality separately
Hear the statutory auditor, internal auditor and quality head without management filtering the issue map.
Days 15–30
Trace inventory evidence
Follow selected batches through status, shelf life, channel returns, valuation and write-off governance.
Days 30–45
Map pipeline accounting
Link research stages, licences, milestones and forecast assumptions to recognition and impairment conclusions.
Days 45–60
Join observation and provision logs
Compare quality, legal and finance views of probability, exposure and remediation timing.
Days 60–80
Test sales-practice controls
Review incentives, samples, discounts, third parties and investigation escalation in a high-risk channel.
Days 80–100
Retarget assurance
Put data integrity, quality-to-finance interfaces and unresolved regulatory commitments into the audit plan.
Questions directors actually ask
Does a healthcare audit chair need sector experience?
It is highly valuable because inventory, research, quality and regulatory evidence create judgements unfamiliar to a general reporting role.
Can a quality event affect financial statements?
Yes. It may affect inventory value, provisions, impairment, revenue, going concern or material-event disclosure depending on facts.
What replaces financial-services regulation?
CDSCO, drugs-and-cosmetics, clinical-trial, pharmacovigilance, quality-system and price-control evidence shape the audit agenda.
Must the chair be a chartered accountant?
No statutory monopoly applies, but the chair must demonstrate financial literacy deep enough to lead estimates, controls and auditor challenge.
How are fee ranges calculated?
They are quartiles from annual-report remuneration records, published only when the sample clears the minimum threshold.
Which Mumbai healthcare audit issues deserve early diligence?
Inventory ageing and returns, R&D arrangements, regulatory observations, quality provisions and sales-practice controls should be traced before accepting the chair.
India ID Exchange Foresight
Deploy our search agent before the shortlist is already written
We read 3,790 boards daily, find the roles that fit your committee, sector and geography, and put the brief, fees and deadline in front of you early.
Start ForesightRelated board-seat resources
- Audit Committee Chair Roles in Healthcare and Pharma Industry in Bengaluru
- Audit Committee Chair Roles in Healthcare and Pharma Industry in India
- Audit Committee Chair Roles in Financial Services Industry in Mumbai
- Audit Committee Chair Roles in Technology Industry in Mumbai
- Audit Committee Chair Roles in Financial Services Industry in Bengaluru
- Audit Committee Chair Roles in Technology Industry in Bengaluru
- All open board seats on India ID Exchange
- Board Seats in India
- Independent Director Salary Benchmark
- Board Marketplace for Companies
- Independent Director Portfolio Builder
- India ID Exchange Membership Benefits
- Board Readiness Assessment
- Independent Directors in India
Before you apply
What this committee is accountable for, what the seat pays, and how much capacity it will take.